The lawsuit, filed in the United States District Court for the Southern District of New York under the caption City of Ann Arbor Retiree Health Care Benefit Plan & Trust v. Zoetis Inc., centers on claims that the animal health firm misled shareholders regarding its operational health. Plaintiffs allege that Zoetis failed to disclose that Librela, a canine pain medication, faced softening adoption rates following FDA warnings about neurological complications. Additionally, the suit claims the company lost significant market share for its flea and tick preventative Simparica Trio, as well as its dermatological staples Apoquel and Cytopoint, to lower-priced competitors.
Zoetis Faces Securities Class Action Over Alleged Misleading Product Growth
Investors who purchased Zoetis Inc. securities between January 14, 2025, and May 6, 2026, are being urged to contact legal counsel following the filing of a securities fraud class action lawsuit. The complaint alleges the company obscured weakening demand and increased market competition for its key veterinary products.
These concerns culminated on May 7, 2026, when Zoetis released its first-quarter financial results. The report revealed a sharp decline in the company’s companion animal business, triggering a 21.5% drop in stock price. Kessler Topaz Meltzer & Check, LLP, a firm specializing in securities litigation, is now coordinating with investors to evaluate recovery options. Those who suffered losses during the specified period have until July 27, 2026, to file for lead plaintiff status. While the firm provides a pathway for legal representation on a contingency fee basis, investors retain the right to select their own counsel or remain as absent class members.
Comments (0)
No comments yet. Be the first!